REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2022

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth in the first quarter of 2022, driven by significant increases in collaboration revenue from key partnerships, particularly with Sanofi and Bayer. While net product sales saw a slight decline year-over-year, largely due to the absence of REGEN-COV sales compared to the prior year's COVID-19 surge, this was more than offset by robust performance in collaboration revenue streams. The company's ongoing investment in research and development remains substantial, reflecting its commitment to pipeline advancement. Financially, Regeneron maintained a healthy cash position and liquidity, supported by strong operating cash flow. The company continued its share repurchase program, returning capital to shareholders. Despite legal proceedings and market uncertainties, Regeneron's diversified portfolio and strategic collaborations position it for continued growth and innovation in the biotechnology sector.

Key Highlights

• 1Total revenues increased by 17% to $2.97 billion, driven by strong collaboration revenue.
• 2Net income decreased by 13% to $973.5 million, or $8.61 per diluted share, compared to the prior year.
• 3Collaboration revenue surged by 47% to $1.46 billion, primarily due to increased profit sharing from Dupixent and Kevzara with Sanofi, and EYLEA sales with Bayer.
• 4Net product sales decreased by 5% to $1.64 billion, mainly due to the absence of REGEN-COV sales compared to the prior year.
• 5Research and development expenses increased by 14% to $843.8 million, reflecting continued investment in pipeline development.
• 6The company repurchased $352 million of its common stock in Q1 2022, with $2.49 billion remaining under its repurchase program.
• 7Regeneron announced an agreement to acquire Checkmate Pharmaceuticals, Inc. for approximately $250 million in April 2022.

Frequently Asked Questions